Epidemiology and Infection · 2012 · 224 citations · 24 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial PharmacotherapyAntibacterial TherapyAntibiotic ResistanceAntimicrobial TherapyCarbapenem ResistanceCombination Antimicrobial TherapyAcinetobacter Baumannii InfectionAcinetobacter Baumannii ResistanceBacterial Pneumonia TreatmentCombination Therapy EvaluationMortality RatesPneumonia Antibiotic TherapyVentilator-associated PneumoniaVentilator-associated Pneumonia Treatment
The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P = 0·654), laboratory (P = 0·645), radiological (P = 0·290) and microbiological (P = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days, P = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (P = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.
24
William A. Knaus, Elizabeth A. Draper, Douglas P. Wagner et al. · Critical Care Medicine · 1985 · 13.7K citations
Medicine, Internal Medicine, Clinical Classification Systems +16
APACHE II: a severity of disease classification system.
Elizabeth S. Draper · PubMed · 1985 · 6.1K citations